Immune Resistance and EGFR Antagonists in Colorectal Cancer



Downloads per month over past year

Giordano, G. and Remo, A. and Porras Gallo, Almudena and Pancione, M. (2019) Immune Resistance and EGFR Antagonists in Colorectal Cancer. Cancers, 11 (8). p. 1089. ISSN 2072-6694

[thumbnail of cancers-11-01089-v2.pdf]
Creative Commons Attribution.


Official URL:


Targeting the epidermal growth factor receptor (EGFR) either alone or in combination with chemotherapy in patients with RAS wild type metastatic colorectal cancer (mCRC) has revolutionized the treatment of CRC, but with less results than initially envisaged. In recent years, the discovery of multiple pathways leading to the escape from anti-EGFR therapy has revealed an enormous complexity and heterogeneity of human CRC due to the intrinsic genomic instability and immune/cancer cell interaction. Therefore, understanding the mechanistic basis of acquired resistance to targeted therapies represents a major challenge to improve the clinical outcomes of patients with CRC. The latest findings strongly suggest that complex molecular alterations coupled with changes of the immune tumor microenvironment may substantially contribute to the clinical efficacy of EGFR antagonist. In this review, we discuss the most recent findings that contribute to both primary and acquired anti-EGFR therapy resistance. In addition, we analyze how strategies aiming to enhance the favorable effects in the tumor microenvironment may contribute to overcome resistance to EGFR therapies.

Item Type:Article
Uncontrolled Keywords:colorectal cancer; EGFR; resistance; targeted therapies; immune microenvironment
Subjects:Medical sciences > Pharmacy > Molecular biology
Medical sciences > Pharmacy > Biochemistry
ID Code:67095
Deposited On:29 Jul 2021 14:39
Last Modified:19 Aug 2021 07:20

Origin of downloads

Repository Staff Only: item control page